新来的2019-03-06 22:50
$Neon Therapeutics(NTGN)$ CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will p...查看全文
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000062 Size: 12 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000063 Size: 12 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000064 Size: 10 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000065 Size: 12 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000066 Size: 8 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000067 Size: 8 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000068 Size: 10 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000069 Size: 10 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000070 Size: 12 KB 网页链接
$Neon Therapeutics(NTGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001694187-20-000071 Size: 10 KB 网页链接